Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

Clinical trial NCT03521245 · UNKNOWN

Trial details

NCT number: NCT03521245
Sponsor: OmicsWay Corp.
Status: UNKNOWN
Study type: OBSERVATIONAL

HER2-positive Breast Cancer

Start date: 2017-10-01
Primary completion: 2021-04-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.